Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Aclaris Bosakitug Phase 2 Trial Misses Primary Endpoint

Aclaris Therapeutics, Inc. filed a Form 8-K on November 16, 2026, disclosing that its Phase 2 ADMIRATION trial of bosakitug (ATI-045) in moderate-to-severe atopic dermatitis did not achieve its primary endpoint, while also announcing the initiation of a new Phase 2b trial and additional …

Aakashdeep | 16 November 2026

Rezolute Prices $93.5M Offering at $3.87 Per Share

Rezolute, Inc. filed a Form 8-K with the SEC on November 16, 2026, disclosing an underwriting agreement dated November 13, 2026, covering an underwritten public offering of common stock and pre-funded warrants expected to generate approximately $93.5 million in net proceeds.

Aakashdeep | 16 November 2026

Oscar Health Adds Cohen, Larsen, Taneja to Board

Oscar Health, Inc. filed a Form 8-K on November 16, 2026, disclosing the appointment of three new independent directors to its Board of Directors, effective November 13, 2026, expanding the board from eight to eleven members.

Nitish Kishor | 16 November 2026

Henry Schein Revises 2026 Non-GAAP EPS Guidance to $5.42-$5.48

Henry Schein, Inc. filed a Form 8-K on November 16, 2026, disclosing a voluntary change to its non-GAAP financial measure presentation and a corresponding update to its full-year 2026 non-GAAP diluted earnings per share guidance.

Aakashdeep | 16 November 2026

Lithium Americas Amends DOE Loan for Thacker Pass Phase 1

Lithium Americas Corp. filed a current report on November 16, 2026, disclosing that on November 10, 2026, it entered into Omnibus Waiver, Consent and Amendment No. 3 with the U.S. Department of Energy and other parties, amending key agreements governing the DOE loan for …

Aditi Sarkar | 16 November 2026

OZ Vision Flags Non-Reliance on Financials Over License Error

OZ Vision Inc. filed a current report on November 16, 2026, disclosing that its Board of Directors concluded investors should no longer rely on the company's previously issued audited financial statements for the fiscal years ended June 30, 2025 and June 30, 2026, due …

Anjali Anand | 16 November 2026

FDA Issues Complete Response Letter for Ivonescimab BLA

Summit Therapeutics Inc. filed a Form 8-K on November 16, 2026, disclosing that the U.S. Food and Drug Administration issued a Complete Response Letter on November 15, 2026, regarding the Biologics License Application for ivonescimab in combination with platinum-containing chemotherapy for certain non-small cell …

Anjali Anand | 16 November 2026

Zymeworks Authorizes $200M Second 2026 Share Repurchase

Zymeworks Inc. filed an 8-K on November 16, 2026, disclosing that its Board of Directors authorized a second 2026 share repurchase program allowing the company to repurchase up to $200.0 million of its outstanding common stock through 2028.

Manish Choudhary | 16 November 2026

Quality Industrial Corp Reports Q3 2026 Financial Results

Quality Industrial Corp. filed a Form 8-K on November 16, 2026, announcing the release of its financial results for the three and nine months ended September 30, 2026, alongside the filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, …

Manish Choudhary | 16 November 2026

XTI Aerospace COO Michael Tapp Resigns Effective Nov. 9

XTI Aerospace, Inc. filed a Form 8-K on November 16, 2026, disclosing that Chief Operating Officer Michael A. Tapp resigned from his position effective immediately on November 9, 2026.

Manish Choudhary | 16 November 2026
Support

Hi! How can we help you today?

Loading…